Neurotech Pharmaceuticals, Inc.: Phase III clinical trials with NT 501 ECT showed statistical significance for the primary endpoint in Macular telangiectasia type 2

Neurotech Pharmaceuticals announced positive topline results in two replicative Phase III clinical trials with NT 501 ECT, their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that results in gradual deterioration of central vision